Valneva Pipeline - https://valneva.com/research-development/ || DEV > https://www.valneva.at/en/general-public
Lyme disease –
VLA15 is the most common vector-borne illness in the Northern Hemisphere. Valneva's candidate is
the only vaccine in clinical development worldwide. Valneva´s vaccine candidate VLA15, under Fast Track Designation by the FDA, is a multivalent vaccine that targets the outer surface protein A (OspA) of Borrelia.
Chikungunya –
VLA1553 is a mosquito-borne viral infection spreading in the Americas and Europe caused by the chikungunya virus (CHIKV), a Togaviridae virus transmitted by Aedes mosquitoes. Valneva’s vaccine candidate
VLA1553, under Fast Track Designation by the FDA, is a monovalent, single dose, live-attenuated vaccine candidate against chikungunya.
COVID-19 –
VLA2001. COVID-19 has caused millions of deaths globally and has been declared a pandemic by the World Health Organization (WHO). To help fight the pandemic, Valneva has developed VLA2001,
currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe.
Zika – VLA1601. A mosquito-borne disease associated with birth defects.
Since 1952, Zika outbreaks have been reported in tropical Africa, Southeast Asia, the Pacific Islands, and, in 2015, in the Americas. Valneva’s vaccine candidate, VLA1601, is a highly purified inactivated vaccine candidate against the
Zika virus, developed using the same manufacturing platform as Valneva’s Japanese encephalitis vaccine.
Clostridium difficile – VLA84. Clostridium difficile is a bacterium that causes diarrhea and sometimes can lead to serious intestinal conditions or complications. Valneva’s prophylactic vaccine candidate against C. difficile infection, VLA84, successfully completed Phase 2 development and is
Phase 3 ready.
STATUS: 12/2021 T W I T T E R https://twitter.com/valnevaSE